Cracking the Code: Finding the Optimal Valuation for Successful Capital Infusion and M&A Deals | LSI USA '24

CEO, Founder, Investor, and proud member of the Medtech ecosystem.

Mr. Ramin Mousavi has executive leadership and operational experience in general management, marketing, strategy, product development, and commercialization across multiple market segments. Most recently, Mr. Mousavi led the patient monitoring and digital health portfolio at Baxter International. Prior to Baxter, he held various leadership assignments at Edwards Lifesciences. Mr. Mousavi served as CathWorks’s, Vice President of Global Marketing and Strategy and the Chief Marketing Officer from 2019 to 2020. Mr. Mousavi holds B.S. degrees in Computer and Electrical Engineering from University of California, Irvine. He also earned an M.B.A. from Paul Merage School of Business at UC Irvine, and received a Healthcare Executive Leadership certificate for Business Innovation in Global Healthcare from Harvard Business School.

Andrew ElBardissi, M.D., is a Partner on the Medical Technologies team and joined the Firm in 2017. Prior to Deerfield, Dr. ElBardissi was a Principal at Longitude Capital, where he focused on investments in medtech and biotechnology. Before that, he was an Associate in JPMorgan’s healthcare investment banking practice. Dr. ElBardissi received residency training in General Surgery at Harvard Medical School’s Brigham and Women’s Hospital and in Cardiothoracic Surgery at Stanford University. He has been independently funded by the National Institutes of Health and the Agency for Healthcare Research and Quality, has authored over 30 publications in leading peer-reviewed scientific journals and has presented his research at numerous medical and surgical conferences. Dr. ElBardissi holds an M.D. from the Mayo Clinic, an M.P.H. in Quantitative Methods from Harvard University, an M.B.A. from Harvard Business School and a B.S. with honors in Biology (Phi Beta Kappa) from the Schreyer Honors College at the Pennsylvania State University.

Paul brings over 35 years of global medical technology management experience to SV.

He joined SV in 2009 as a Venture Partner and in 2011 was made a Partner. Paul was promoted to Managing Partner & COO in 2014 and heads our medical device investments.

Prior to SV, Paul built and ran medical device businesses for 29 years before joining SV Health Investors. Most recently he was Chief Operating Officer at Boston Scientific (BSC), an $8 billion medical device leader. During his 15 years at BSC, Paul served as Chief Operating Officer; Group President, Cardiovascular; President, Cardiology; Group President, Endosurgery; and President, International. During his tenure, the company grew revenue over 20 times. Paul integrated two dozen acquisitions and led extensive product development, manufacturing and worldwide commercial organizations. Previously, Paul held marketing and general management positions at CR Bard and various marketing roles at Kendall (Medtronic).

Outside of SV, Paul serves on the board of Edwards Lifesciences Corporation and the Medical Device Manufacturers Association, and is Chairman of the Innovation Growth Board at the Mass General Brigham health system. In addition, Paul serves on the board of Vibrato Medical, Inc. as a Director. He also served on the board of Advamed for 10 years and is a routine speaker at industry meetings.

With over thirty years of experience founding and funding healthcare companies, Jay Watkins is a veteran of the medtech industry. Mr. Watkins career in healthcare began when he co-founded Origin Medsystems in the late 1980’s, a venture funded medical technology start-up that was subsequently acquired by Eli Lilly & Company. After Lilly formed Guidant, he joined the Management Committee and served as president of several divisions, including the Minimally Invasive Surgery Group, and Heart Rhythm Technologies. While at Guidant, Mr. Watkins initiated the development of a minimally invasive vein harvesting technology which has been used to treat more than three million patients worldwide; he also co-founded Gynecare, a women’s health care company which was spun out, taken public, and subsequently acquired by Johnson & Johnson.  In addition, he was the founding President of Compass, Guidant’s corporate business development and new ventures group where he led venture investments in fourteen companies including Impella (acquired by Abiomed; NASDAQ: ABMD) and Intuitive Surgical (NASDAQ: ISRG).  Most recently Mr. Watkins was a general partner at De Novo Ventures where he represented the firm’s investments in several healthcare companies including Lumend (sold to Johnson and Johnson), Precision Light (sold to Allergan), Loma Vista (sold to CR Bard). He is an active individual investor and currently serves as Chairman of Reflexion Medical and Avail Medsystems. He served as Chairman of Recor Medical before its sale to Otsuka Holdings in 2017. He also served as Chairman of Shockwave prior to its public offering in 2019 and continues to serve as a member of the Board (NASDAQ: SWAV).  

Prior to founding Origin, Mr. Watkins held management positions in several start-ups, including Microgenics Corporation (acquired by Boehringer Mannheim), and was a consultant with McKinsey & Company. Mr. Watkins teaches at the Stanford Byers Center for Biodesign and is a Lecturer in Management at the Graduate School of Business, Stanford University. Mr. Watkins received his MBA from Harvard Business School and his undergraduate degree from Stanford University.